|
Jun 20
|
We're A Little Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
|
|
Jun 17
|
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
|
|
Jun 16
|
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
|
|
Aug 29
|
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Aug 28
|
Favourable Signals For Immuneering: Numerous Insiders Acquired Stock
|
|
Jan 9
|
With 37% ownership, Immuneering Corporation (NASDAQ:IMRX) has piqued the interest of institutional investors
|
|
Nov 29
|
Here's Why We're Watching Immuneering's (NASDAQ:IMRX) Cash Burn Situation
|
|
Oct 4
|
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
|